[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Steed ME, Vidaillac C, Rybak MJ: Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother; 2010 Dec;54(12):5187-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although infections with daptomycin-nonsusceptible (DNS) MRSA are infrequent, optimal therapy of these strains has not been determined.
  • We investigated the killing effects of novel antibiotic combinations with daptomycin (DAP) against two clinical DNS MRSA isolates (SA-684 and R6003) in a 72-h in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations (SEV).
  • The unique combination of DAP plus TMP/SMX was the most effective and rapidly bactericidal regimen against the two isolates tested and may provide a clinical option to treat DNS S. aureus infections.
  • [MeSH-major] Anti-Infective Agents / pharmacology. Daptomycin / pharmacology. Methicillin-Resistant Staphylococcus aureus / drug effects
  • [MeSH-minor] Acetamides / pharmacology. Cephalosporins / pharmacology. Drug Combinations. Endocarditis, Bacterial / microbiology. Linezolid. Microbial Sensitivity Tests. Nafcillin / pharmacology. Oxazolidinones / pharmacology. Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology

  • MedlinePlus Health Information. consumer health - MRSA.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. NAFCILLIN .
  • Hazardous Substances Data Bank. LINEZOLID .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Ther. 2000 Jan;22(1):66-75 [10688391.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Oct;53(10):4127-32 [19635961.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Feb;45(2):454-9 [11158740.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jun;45(6):1799-802 [11353628.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jun;45(6):1843-6 [11353635.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Aug;46(8):2606-12 [12121940.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Aug;47(8):2682-4 [12878541.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jan;48(1):63-8 [14693519.001]
  • [Cites] J Antimicrob Chemother. 1985 Jan;15 Suppl A:125-30 [3980323.001]
  • [Cites] Antimicrob Agents Chemother. 1987 Dec;31(12):1982-8 [3439805.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Dec;36(12):2709-14 [1336344.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72 [15561842.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jan;49(1):302-8 [15616309.001]
  • [Cites] Ann Pharmacother. 2005 Mar;39(3):427-32 [15701775.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jul;49(7):2735-45 [15980344.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45 [16723576.001]
  • [Cites] Int J Antimicrob Agents. 2006 Oct;28(4):280-7 [16963232.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Oct;50(10):3245-9 [17005801.001]
  • [Cites] Diagn Microbiol Infect Dis. 2007 Apr;57(4):459-65 [17240105.001]
  • [Cites] J Antimicrob Chemother. 2007 Aug;60(2):334-40 [17540670.001]
  • [Cites] Clin Infect Dis. 2007 Sep 1;45(5):601-8 [17682996.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8 [17620372.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jan;52(1):269-78 [17954690.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Mar;52(3):831-6 [17999971.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):433-7 [18214559.001]
  • [Cites] Diagn Microbiol Infect Dis. 2008 Jun;61(2):235-9 [18314293.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2223-5 [18378708.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2156-62 [18411321.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Sep;52(9):3061-7 [18591272.001]
  • [Cites] J Antimicrob Chemother. 2008 Dec;62(6):1305-10 [18801920.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Dec 1;178(11):1180-5 [18787216.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Jun;53(6):2636-7 [19289517.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Jun;53(6):2312-8 [19332678.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Sep;53(9):3981-4 [19564361.001]
  • [Cites] Diagn Microbiol Infect Dis. 2009 Oct;65(2):158-62 [19748426.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jul;44(7):1925-9 [10858356.001]
  • (PMID = 20921318.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Anti-Infective Agents; 0 / Cephalosporins; 0 / Drug Combinations; 0 / Oxazolidinones; 4CNZ27M7RV / Nafcillin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 807PW4VQE3 / cefepime; ISQ9I6J12J / Linezolid; NWQ5N31VKK / Daptomycin
  • [Other-IDs] NLM/ PMC2981245
  •  go-up   go-down


2. Bayerl Ch: Beta-carotene in dermatology: Does it help? Acta Dermatovenerol Alp Pannonica Adriat; 2008 Dec;17(4):160-2, 164-6
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Beta-carotene should be used in erythropoietic protoporphyria, photosensitive diseases, and to reduce the effects of phototoxic drugs.
  • [MeSH-major] Vitamins / therapeutic use. beta Carotene / therapeutic use
  • [MeSH-minor] Dysplastic Nevus Syndrome / drug therapy. Erythema / drug therapy. Food. Food Analysis. Humans. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Vitamins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104740.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Vitamins; 01YAE03M7J / beta Carotene
  • [Number-of-references] 51
  •  go-up   go-down


3. Adedoyin OT, Johnson AW, Ojuawo AI, Afolayan EA, Adeniji KA: Malignant melanoma in a black child: predisposing precursors and management. J Natl Med Assoc; 2004 Oct;96(10):1368-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma in a black child: predisposing precursors and management.
  • Malignant melanoma (MM) remains a pediatric rarity world-wide, but perhaps more so in black Africans.
  • To the best of our knowledge, the current report of MM in a two-and-a-half-year-old Nigerian who had a pre-existing congenital giant hairy nevus is probably the first (in an accessible literature) in a black African child.
  • Primary neoplastic transformation and metastatic spread were suggested by the appearance of multiple swellings over the "garment" precursor nevus at the posterior trunk, multiple ipsilateral axillary nodal enlargement, and fresh occipital swellings postadmission.
  • Chemotherapy was initiated but was truncated shortly after by parent-pressured discharge.
  • Despite the rarity of MM in a tropical African setting where management options are few, the current case underscores the need for a high clinical index of diagnostic suspicion, an early pursuit of investigative confirmation, and prophylactic excision in children with the predisposing skin lesions, like congenital giant hairy nevus.
  • [MeSH-major] African Continental Ancestry Group / genetics. Dysplastic Nevus Syndrome / complications. Melanoma / etiology. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 1999 May;63(5):293-8 [10349545.001]
  • [Cites] J Am Med Assoc. 1951 Nov 3;147(10):941-3 [14873600.001]
  • [Cites] Arch Dermatol. 1965 Feb;91:100-19 [14237589.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] Br J Dermatol. 1968 Jun;80(6):362-6 [5701724.001]
  • [Cites] Pediatrics. 1975 Feb;55(2):191-204 [1090894.001]
  • [Cites] Arch Dermatol. 1975 Dec;111(12):1658 [1200672.001]
  • [Cites] Br J Plast Surg. 1977 Oct;30(4):321-3 [588799.001]
  • [Cites] JAMA. 1978 Feb 20;239(8):744-6 [621895.001]
  • [Cites] JAMA. 1979 Dec 21;242(25):2795-9 [501893.001]
  • [Cites] J Am Acad Dermatol. 1979 Aug;1(2):123-30 [391836.001]
  • [Cites] J Am Acad Dermatol. 1979 Dec;1(6):503-5 [528699.001]
  • [Cites] Br J Dermatol. 1981 Mar;104(3):307-15 [7213564.001]
  • [Cites] Plast Reconstr Surg. 1981 Jun;67(6):782-90 [7243980.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1229-34 [6491702.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1720-3 [3651999.001]
  • [Cites] Important Adv Oncol. 1988;:217-57 [3042605.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):199-203 [2910418.001]
  • [Cites] J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):159-76 [2179292.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):438-41 [2009058.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1403-8 [2072144.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5074s-5079s [1884383.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):43-6 [7804976.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):656-62 [7845431.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):334-6 [7638982.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1833-45 [8625056.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8 [8703684.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]
  • [Cites] Ann Surg. 1997 Jan;225(1):1-14 [8998115.001]
  • [Cites] Melanoma Res. 1997 Feb;7(1):63-8 [9067967.001]
  • [Cites] Curr Opin Pediatr. 1998 Aug;10(4):398-404 [9757365.001]
  • [Cites] J Dermatol Surg Oncol. 1978 Feb;4(2):153-8 [624799.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • (PMID = 15540891.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2568537
  •  go-up   go-down


Advertisement
4. Chuang KH, Cheng CM, Roffler SR, Lu YL, Lin SR, Wang JY, Tzou WS, Su YC, Chen BM, Cheng TL: Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. Bioconjug Chem; 2006 May-Jun;17(3):707-14
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
  • Combination therapy can help overcome limitations in the treatment of heterogeneous tumors.
  • In the current study, we examined whether multiple therapeutic agents could be targeted to anti-dansyl single-chain antibodies (DNS scFv) that were anchored on the plasma membrane of cancer cells.
  • Functional DNS scFv could be stably expressed on CT-26 colon cancer cells both in vitro and in vivo.
  • Dansyl moieties were covalently attached to recombinant beta-glucuronidase (betaG) and interleukin 2 (IL-2) via a flexible poly(ethylene glycol) linker to form DNS-PEG-betaG and DNS-PEG-IL-2 conjugates.
  • The conjugates selectively bound CT-26 cells that expressed anti-DNS scFv (CT-26/DNS cells) but not CT-26 cells that expressed control scFv (CT-26/phOx cells).
  • DNS-PEG-betaG preferentially activated a glucuronide prodrug (BHAMG) of p-hydroxy aniline mustard at CT-26/DNS cells in culture and accumulated in subcutaneous CT-26/DNS tumors after intravenous administration.
  • Systemic administration of DNS-PEG-IL-2 or DNS-PEG-betaG and BHAMG significantly delayed the growth of CT-26/DNS but not control CT-26/phOx tumors.
  • Combination treatment with DNS-PEG-betaG and BHAMG followed by DNS-PEG-IL-2 therapy significantly suppressed the growth of CT-26/DNS tumors as compared to either single-agent regimen.
  • These results show that at least two DNS-modified therapeutic agents can be selectively delivered to DNS scFv receptors in vitro and in vivo, allowing combination therapy of DNS scFv-modified tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Glucuronidase / pharmacology. Haptens / immunology. Interleukin-2 / pharmacology. Neoplasms / drug therapy. Neoplasms / immunology. Prodrugs / metabolism
  • [MeSH-minor] Animals. Antibodies / immunology. Cell Line, Tumor. Drug Therapy, Combination. Mice. Mice, Inbred BALB C. Polyethylene Glycols / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704208.001).
  • [ISSN] 1043-1802
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antineoplastic Agents; 0 / Haptens; 0 / Interleukin-2; 0 / Prodrugs; 30IQX730WE / Polyethylene Glycols; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


5. Turner C, Pateman B: A study of district nurses' experiences of continuous ambulatory chemotherapy. Br J Community Nurs; 2000 Aug;5(8):396-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of district nurses' experiences of continuous ambulatory chemotherapy.
  • As a result of technical developments and policies that promote shorter hospital stays, patients are increasingly receiving high technology treatment in the community.
  • The administration of ambulatory intravenous chemotherapy at home is an example of such treatment.
  • Despite being generalist nurses, district nurses (DNs) are involved in what could be viewed as 'specialist' care - advising and supporting patients while they are receiving treatment.
  • This article reports on a study of 20 DNs from one community trust and examines the sources of the knowledge and skills used in caring for these patients and the communication links with the regional cancer centre.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Community Health Nursing. Home Infusion Therapy / nursing. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12271233.001).
  • [ISSN] 1462-4753
  • [Journal-full-title] British journal of community nursing
  • [ISO-abbreviation] Br J Community Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Raza ML, Zeeshan M, Ahmad M, Shaheen F, Simjee SU: Anticonvulsant activity of DNS II fraction in the acute seizure models. J Ethnopharmacol; 2010 Apr 21;128(3):600-5
Hazardous Substances Data Bank. ACETONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticonvulsant activity of DNS II fraction in the acute seizure models.
  • Other species of Delphinium are reported as anticonvulsant and are traditionally used in the treatment of epilepsy.
  • DNS II acetone was chosen for further testing in the acute seizure models of epilepsy to study the antiepileptic potential in male mice.
  • MATERIALS AND METHODS: Different doses (60, 65 and 70mg/kg, i.p.) of DNS II acetone fraction of Delphinium nordhagenii was administered 30min prior the chemoconvulsant's injection in the male mice.
  • Moreover, four different doses of DNS II (60, 65, 70 and 100mg/kg, i.p.) were tested in the MES test.
  • RESULTS: The DNS II acetone fraction of Delphinium nordhagenii has exhibited the anticonvulsant actions by preventing the seizures against PTZ- and picrotoxin-induced seizure as well as 100% seizure protection in MES test.
  • [MeSH-major] Anticonvulsants / therapeutic use. Epilepsy / drug therapy. Epilepsy / prevention & control. Seizures / drug therapy. Seizures / prevention & control
  • [MeSH-minor] Acetone / therapeutic use. Animals. Delphinium / chemistry. Diazepam / therapeutic use. Male. Melanoma / drug therapy. Mice. Mice, Inbred Strains. Pakistan. Pentylenetetrazole / therapeutic use. Phenytoin / therapeutic use. Picrotoxin / therapeutic use. Ranunculaceae / chemistry. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Seizures.
  • Hazardous Substances Data Bank. PICROTOXIN .
  • Hazardous Substances Data Bank. DIAZEPAM .
  • Hazardous Substances Data Bank. PHENYTOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20138136.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anticonvulsants; 124-87-8 / Picrotoxin; 1364PS73AF / Acetone; 6158TKW0C5 / Phenytoin; Q3JTX2Q7TU / Diazepam; WM5Z385K7T / Pentylenetetrazole
  •  go-up   go-down


7. van Bussel B, Pijpers E, Ferreira I, Castermans P, Kruseman AN: Polymorbidity in diabetes in older people: consequences for care and vocational training. Postgrad Med J; 2007 Dec;83(986):763-7
MedlinePlus Health Information. consumer health - Diabetes Complications.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the prevalence of complicating and concurrent morbidities in older diabetic patients and to evaluate to what extent their occurrence affects the burden of disease and use of medical healthcare.
  • Healthcare registration systems were used to retrieve data on 300 patients with diabetes aged >or=60 years who, according to the severity of their disease and intensity of care required, were treated in a regional general practitioner (GP), diabetes nurse specialist (DNS) or medical specialist (MS) practice.
  • RESULTS: Complicating and concurrent morbidities were often found irrespective of the type of practice involved.
  • After adjustments for differences in sex, age and glycosylated haemoglobin (HbA1c), the extent of complicating comorbidities showed sequential increases in patients managed by GP, DNS and MS (mean number of 3.6, 4.7 and 6.7, respectively; p(trend)<0.001).
  • Both complicating and concurrent comorbidities were similarly associated with the extent of drug use (beta = 0.49 (95% CI 0.40 to 0.58) and beta = 0.57 (95% CI 0.52 to 0.72), respectively) and the number of consultations with specialists other than the main care giver (beta = 1.19 (95% CI 1.15 to 1.24) and beta = 1.21 (95% CI 1.14 to 1.28), respectively).
  • CONCLUSIONS: The use of healthcare facilities by older patients with diabetes is substantial, irrespective of the complexity of the disease and the kind of practice involved.
  • The common manifestation of complicating and concurrent comorbidities and their varying complexity in individual patients requires a patient-oriented rather than a disease-oriented approach and vocational training programmes for care givers that are tailored to the complexity of multiple chronic diseases.
  • [MeSH-major] Diabetes Complications / therapy
  • [MeSH-minor] Aged. Blood Glucose. Chronic Disease. Cost of Illness. Cross-Sectional Studies. Female. Humans. Hypoglycemic Agents / therapeutic use. Male. Middle Aged. Patient Acceptance of Health Care. Polypharmacy. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2000 Feb 26;320(7234):569-72 [10688568.001]
  • [Cites] Med Care. 2007 Jan;45(1):55-65 [17279021.001]
  • [Cites] J Clin Epidemiol. 2001 Jul;54(7):680-6 [11438408.001]
  • [Cites] BMJ. 2001 Oct 27;323(7319):983-5 [11679390.001]
  • [Cites] BMJ. 2002 Oct 26;325(7370):925 [12399340.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):221-9 [12725876.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Clin Epidemiol. 1993 May;46(5):469-73 [8501473.001]
  • [Cites] J Clin Epidemiol. 1994 Nov;47(11):1245-51 [7722560.001]
  • [Cites] Control Clin Trials. 1998 Dec;19(6):589-601 [9875838.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2870-4 [15625341.001]
  • [Cites] BMJ. 2005 Mar 19;330(7492):609-10 [15774963.001]
  • [Cites] BMJ. 2005 Mar 19;330(7492):662-5 [15775001.001]
  • [Cites] Acad Med. 2005 May;80(5):507-12 [15851467.001]
  • [Cites] Am J Med. 2005 Jun;118(6):680-5; discussion 685-7 [15922702.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):474-80 [15998827.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):716-24 [16091574.001]
  • [Cites] Health Qual Life Outcomes. 2005;3:74 [16305743.001]
  • [Cites] Chest. 2006 Feb;129(2):285-91 [16478843.001]
  • [Cites] Lancet. 2006 Feb 18;367(9510):550-1 [16488782.001]
  • [Cites] BMC Health Serv Res. 2006;6:84 [16820048.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):13-22 [17242667.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):453-71 [10717521.001]
  • (PMID = 18057176.001).
  • [ISSN] 1469-0756
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hypoglycemic Agents
  • [Other-IDs] NLM/ PMC2750927
  •  go-up   go-down


8. Ravot E, Comolli G, Lori F, Lisziewicz J: High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment. J Gene Med; 2002 Mar-Apr;4(2):161-9
Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment.
  • BACKGROUND: Gene therapy has recently been advanced by the development of HIV-based vectors that are able to transduce some non-dividing cells.
  • In this study, a novel delivery strategy is developed to improve significantly the efficiency of HIV-based vectors in transducing non-dividing cells.
  • METHODS: Mature human monocyte-derived macrophages (14-21 days old) were transduced at a low multiplicity of infection (MOI) of HIV vectors carrying a reporter gene. dNSs were added to the medium during transduction (5 mM dNS) and immediately before post-transduction culture (2.5 mM dNS).
  • RESULTS: The addition of dNS to the medium significantly enhanced the efficiency of transduction of human macrophages by HIV-based vectors.
  • The percentage of cells expressing the transgene rose up to 50% in the presence of dNS, increasing the basal transduction levels up to 35-fold (average=10.8-fold).
  • Furthermore, treatment with dNTP precursors compensated for the wide inter-donor variability, allowing the highest enhancement effects in donors with the lowest basal transduction efficiencies.
  • CONCLUSIONS: This is the first demonstration that a single treatment of non-dividing target cells with exogenous dNS can enhance the efficiency of lentiviral-mediated transduction of cells, allowing for high efficiency gene transfer.
  • This simple approach might be transferred to a broader range of quiescent cell types that are scarcely susceptible to lentiviral-based gene delivery due to low dNTP levels.
  • [MeSH-minor] 3T3 Cells. Animals. Cell Division. Cell Line. Dose-Response Relationship, Drug. HIV / genetics. Humans. Macrophages / metabolism. Mice. Retroviridae / genetics. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Time Factors. Transduction, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 11933217.001).
  • [ISSN] 1099-498X
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 533-67-5 / Deoxyribose
  •  go-up   go-down


9. Lipkowski AW, Misicka A, Kosson D, Kosson P, Lachwa-From M, Brodzik-Bienkowska A, Hruby VJ: Biological properties of a new fluorescent biphalin fragment analogue. Life Sci; 2002 Jan 11;70(8):893-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper presents data that replacement of the phenylalanine with a dansyl (X=DNS) groups gives an analogue (AA2016) that fully preserves the high affinity of the initial analogue for both mu and delta opioid receptors.
  • Because AA2016 contains a strong fluorescent group, it can be a very useful tool for prospective studies in vivo, including biological barrier permeability, tissue distribution, metabolism and receptor-ligand complex formation.
  • [MeSH-minor] Analgesia. Animals. Dansyl Compounds. Male. Pain / drug therapy. Pain / metabolism. Phenylalanine. Rats. Rats, Wistar. Receptors, Opioid, delta / metabolism. Receptors, Opioid, mu / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11853227.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA 06284
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Dansyl Compounds; 0 / Enkephalins; 0 / Fluorescent Dyes; 0 / Receptors, Opioid, delta; 0 / Receptors, Opioid, mu; 47E5O17Y3R / Phenylalanine; 83916-01-2 / biphalin
  •  go-up   go-down


10. Reutter JC, Long EM, Morrell DS, Thomas NE, Groben PA: Eruptive post-chemotherapy in situ melanomas and dysplastic nevi. Pediatr Dermatol; 2007 Mar-Apr;24(2):135-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eruptive post-chemotherapy in situ melanomas and dysplastic nevi.
  • A 22-year-old white man without a personal or family history of atypical nevi had received chemotherapy for pre-B-cell acute lymphocytic leukemia at age 17 that included L-asparaginase, prednisone, methotrexate, mercaptopurine, daunorubicin, and cytoxan.
  • Two to three months after completing maintenance chemotherapy, the patient reports he developed many moles, which remained stable for approximately 2 years.
  • Upon examination, two dark, atypical appearing plaques with irregular borders and numerous pink papules of varying shapes and sizes were noted on his chest, back, and abdomen.
  • Histology of specimens of both types of lesions revealed three moderately atypical compound dysplastic melanocytic nevi and three in situ melanomas.
  • The lesions with only features of dysplastic nevi exhibited dermal fibrosis, cytologic atypia, junctional shoulders, lentiginous spread, and focal pigmentation.
  • Malignant melanoma has been associated with chronic immunosuppression, and benign nevi have been reported to erupt after chemotherapy.
  • We report an occurrence of multiple eruptive dysplastic nevi and in situ melanomas appearing shortly after completion of chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Drug Eruptions / etiology. Dysplastic Nevus Syndrome / chemically induced. Immunosuppressive Agents / adverse effects. Melanoma / chemically induced. Skin Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461808.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


11. Shah SA, Sajid T, Asif M, Khan F, Haroon T, Malik S, Ghani R: Evaluation of efficacy of management protocol in allergic rhinitis. J Ayub Med Coll Abbottabad; 2007 Jul-Sep;19(3):6-9
Genetic Alliance. consumer health - Allergic rhinitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: This prospective study was conducted in the Department of Ear, Nose & Throat and Head & Neck Surgery, Ayub Teaching Hospital, Abbottabad, over a period of two years (2005 - 2006), to assess the efficacy of a standard protocol of treatment developed and followed in the department.
  • All the patients were prescribed medical treatment, divided into initial phase of 10 days to two weeks duration followed by a maintenance phase, and a regular follow-up schedule was maintained upto two years.
  • 37.53% patients had surgery done for associated pathologies, mostly a DNS.
  • Compliance regarding medication was more than 90% in the initial phase of treatment that dropped to 50% in the maintenance phase.
  • 93% of the patients tolerated the treatment well.
  • Optimal treatment protocol is still lacking especially in the developing countries.
  • Associated problems that may need surgical treatment.
  • Regular follow-up must be ensured to monitor the progress of treatment as well as to identify patients who might be candidates for immunotherapy.
  • Newer modalities of treatment need to be further explored.
  • [MeSH-major] Rhinitis, Allergic, Perennial / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Clinical Protocols. Female. Humans. Infant. Male. Middle Aged. Patient Education as Topic. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444581.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


12. Quezada G, Kopp L, Estey E, Wells RJ: All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatr Blood Cancer; 2008 Jul;51(1):133-5
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
  • Treatment of pediatric APL is based on the combination of all-trans-retinoic acid (ATRA), an anthracycline and cytosine arabinoside.
  • Arsenic trioxide (ATO) has been studied in adults with newly diagnosed or relapsed APL with excellent response rates both when used as a single agent or in combination with ATRA or ATRA plus chemotherapy.
  • There is little data on combination therapy with ATRA and ATO in pediatric APL.
  • We present a case of an adolescent male with APL who was treated using ATRA and ATO without conventional chemotherapy agents.
  • [MeSH-major] Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Disease-Free Survival. Dysplastic Nevus Syndrome. Humans. Male

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18293388.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


13. McKenna DB, Doherty VR, McLaren KM, Hunter JA: Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology? Br J Dermatol; 2000 Jul;143(1):171-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology?
  • We report seven patients who developed malignant melanoma either coincident with or before the diagnosis of non-Hodgkin's lymphoma or chronic lymphatic leukaemia.
  • One patient died secondary to leukaemia, and chemotherapy-induced immunosuppression may have contributed to the development of metastatic melanoma in another patient.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / etiology. Melanoma / etiology. Neoplasms, Multiple Primary / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Aged. Dysplastic Nevus Syndrome / complications. Female. Humans. Immune System / radiation effects. Immunosuppressive Agents / adverse effects. Male. Middle Aged. T-Lymphocytes, Regulatory / immunology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10886155.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


14. Campbell T, Felsten L, Moore J: Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome. Arch Dermatol; 2009 Nov;145(11):1313-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome.
  • Imatinib mesylate is an inhibitor of c-kit and is indicated in the treatment of chronic myeloid leukemia and GISTs.
  • OBSERVATIONS: A 45-year-old woman with a history of multiple dysplastic nevi and lentigines was diagnosed as having familial GIST syndrome.
  • Treatment with imatinib mesylate was started in an attempt to decrease the tumor load.
  • Three months after treatment initiation, the patient noted a decrease in the number of pigmented lesions, lightening of the skin in her genital area, and graying of her terminal hair.
  • CONCLUSIONS: The potential association between a specific genetic mutation and pigmentation changes secondary to imatinib therapy may account for the variety in presentation of this potential side effect.
  • Further genetic studies paired with melanocyte-specific or c-kit-specific stains of affected tissue are warranted to better understand the relationship between the genetic mutation and the effect of imatinib on pigmentation.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Gastrointestinal Stromal Tumors / complications. Gastrointestinal Stromal Tumors / drug therapy. Lentigo / complications. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Chemotherapy, Adjuvant. Colectomy / methods. Dysplastic Nevus Syndrome / complications. Dysplastic Nevus Syndrome / drug therapy. Dysplastic Nevus Syndrome / genetics. Female. Follow-Up Studies. Humans. Imatinib Mesylate. Middle Aged. Risk Assessment. Treatment Outcome

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917964.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


15. Bayerl C, Schwarz B, Jung EG: A three-year randomized trial in patients with dysplastic naevi treated with oral beta-carotene. Acta Derm Venereol; 2003;83(4):277-81
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A three-year randomized trial in patients with dysplastic naevi treated with oral beta-carotene.
  • Ultraviolet irradiation provokes the development of new melanocytic naevi, or changes in existing naevi, leading to repeated surgery of atypical naevi and becoming a continual burden for individuals with many of these lesions.
  • To determine the influence of long-term medication with the radical scavenger beta-carotene on newly developing atypical naevi, a single-centre, randomized, placebo-controlled study, prospective over 3 years, was started double-blind in 62 patients with numerous clinically atypical naevi.
  • Beta-carotene (25 mg) was given twice daily for 36 months in the treatment group (n = 30) and saccharose capsules as placebo in the control group (n = 32).
  • The total number of newly developed naevi in the beta-carotene group (n = 18) was 68 versus 88 in the placebo group (n=21) (not significant).
  • Overall, it is concluded that beta-carotene does not reduce the development of new naevi in patients with numerous atypical naevi.
  • [MeSH-major] Dysplastic Nevus Syndrome / drug therapy. beta Carotene / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Double-Blind Method. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12926799.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 01YAE03M7J / beta Carotene
  •  go-up   go-down


16. Dow GS, Armson A, Boddy MR, Itenge T, McCarthy D, Parkin JE, Thompson RC, Reynoldson JA: Plasmodium: assessment of the antimalarial potential of trifluralin and related compounds using a rat model of malaria, Rattus norvegicus. Exp Parasitol; 2002 Mar;100(3):155-60
Hazardous Substances Data Bank. CHLOROQUINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other DNs which have better absorption characteristics than either trifluralin or oryzalin may offer more scope for antimalarial activity in vivo.
  • [MeSH-major] Malaria / drug therapy. Plasmodium berghei / drug effects. Sulfanilamides. Trifluralin / pharmacology. Trifluralin / therapeutic use
  • [MeSH-minor] Animals. Antimalarials / pharmacology. Antimalarials / therapeutic use. Cells, Cultured. Chloroquine / pharmacology. Chloroquine / therapeutic use. Dinitrobenzenes / pharmacology. Dinitrobenzenes / therapeutic use. Disease Models, Animal. Erythrocytes / parasitology. Parasitic Sensitivity Tests / methods. Rats. Rats, Inbred Lew

  • MedlinePlus Health Information. consumer health - Malaria.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRIFLURALIN .
  • Hazardous Substances Data Bank. ORYZALIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12173400.001).
  • [ISSN] 0014-4894
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Dinitrobenzenes; 0 / Sulfanilamides; 662E385DWH / oryzalin; 886U3H6UFF / Chloroquine; C8BX46QL7K / Trifluralin
  •  go-up   go-down


17. Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC: Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol; 2006 Jan;5(1):56-62
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study.
  • OBJECTIVE: To assess the clinical and histologic effects of topical imiquimod therapy on dysplastic nevi, and to determine the feasibility of using in vivo confocal microscopy (CSLM) to non-invasively monitor histological response of dysplastic nevi to imiquimod therapy.
  • DESIGN: Single-blinded pilot study with patients not blinded as to treatment status.
  • PATIENTS: The study population comprised of 10 patients with clinically dysplastic (atypical) nevi and at least 8 large nevi, (> or =5 mm) on their trunk.
  • INTERVENTION: Sixteen weeks of imiquimod 5% cream applied to treatment lesions 3 times per week.
  • MAIN OUTCOME MEASURE: Clinical response as gauged by comparison of baseline and week 20 1:1 standardized photographs for all study nevi and histological assessment of each patient's 4 largest study nevi at completion of therapy.
  • RESULTS: There were no obvious clinical changes in the size and morphology of the study nevi.
  • Subtle changes in nevus color could not be assessed due to imperfect spectral registration of images over the course of the study.
  • Histologically, 4 of 14 treated nevi and 0 of 14 untreated nevi p=0.03 showed a significant relative reduction of junctional and intraepidermal nevocytes accompanied by papillary dermal fibroses and variable inflammation suggestive of partial regression.
  • Non-invasive CSLM imaging of study nevi demonstrated previously reported in vivo features of dysplastic nevi. but the imaging equipment and protocol utilized proved inconsistent across lesions and time.
  • CONCLUSIONS: The histological changes seen in a subset of treated nevi suggest a possible role for the use of topical immune response modifiers for the treatment of dysplastic nevi with the intent of melanoma chemoprevention.
  • Targeting of dysplastic nevi and intermediate endpoints for melanoma chemoprevention with more intense and/or prolonged treatment regimens with imiquimod or the use of other immune response modifiers seems promising.
  • Technical improvements are required for the use of non-invasive CSLM imaging in lieu of invasive histology for the study of topical nevus therapies.
  • [MeSH-major] Aminoquinolines / administration & dosage. Dysplastic Nevus Syndrome / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468293.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


18. Jen M, Murphy M, Grant-Kels JM: Childhood melanoma. Clin Dermatol; 2009 Nov-Dec;27(6):529-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood melanoma.
  • Pediatric melanoma is rare but increasing in incidence.
  • Because early diagnosis and treatment improves prognosis, clinicians need to include it as a possible diagnosis when evaluating a pigmented lesion in a pediatric patient.
  • Some risk factors for melanoma include xeroderma pigmentosum, giant congenital melanocytic nevi, dysplastic nevus syndrome, atypical nevi, many acquired melanocytic nevi, family history of melanoma, and immunosuppression.
  • Definitive treatment is with surgical excision.
  • Adjuvant therapies such as chemotherapy, immunotherapy, and radiation therapy can be used in advanced cases.
  • [MeSH-major] Melanoma / pathology. Neoplasm Invasiveness / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Age Factors. Biopsy, Needle. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Early Detection of Cancer. Female. Humans. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880040.001).
  • [ISSN] 1879-1131
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 117
  •  go-up   go-down


19. Shiose Y, Kuga H, Ohki H, Ikeda M, Yamashita F, Hashida M: Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates. Bioconjug Chem; 2009 Jan;20(1):60-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates.
  • The primary purpose of this study was to comprehensively delineate specificity of the peptide spacer sequence to tumor-expressed proteases for the design of macromolecular carrier-peptide spacer-drug conjugate system.
  • 225 conjugates of carboxymethyldextran polyalcohol (CM-Dex-PA) as water-soluble carrier and a dansyl derivative (N-(4-aminobutyl)-5-(dimethylamino)-1-naphthalenesulfonamide, DNS) as the model drug linked with different tetrapeptide spacers (Gly-Gly-P(2)-P(1), P(2), P(1): Ala, Asn, Gly, Cit, Gln, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) were combinatorially synthesized.
  • First, the drug release assay of all of the fluorogenic model conjugates was performed in murine Meth A solid tumor homogenates.
  • The drug release rate was higher with conjugates having hydrophobic amino acids at P(2).
  • It was also found that conjugates with Asn release the drug rapidly and, in contrast, those with Pro does not.
  • Second, we selected three peptide spacers (Gly-Gly-Phe-Gly, Gly-Gly-Ile-Gly, Gly-Gly-Pro-Leu), which release only DNS at different rates, and applied them to doxorubicin (DXR) conjugates.
  • These three DXR conjugates were used for investigating relationships with drug release, pharmacokinetics, and antitumor activity against Meth A bearing mice of these conjugates.
  • The release of DXR from the conjugates corresponded well with that of DNS conjugates in tumor homogenates.
  • Taken with the fact that the drug release rate in tumor homogenates was approximately 10-fold different between these two DXR conjugates, it is likely that cellular uptake of the conjugate would be rate-limiting, rather than the drug release process under the in vivo situation.
  • However, much weaker antitumor activity was observed with CM-Dex-PA-Gly-Gly-Pro-Leu-DXR, of which the drug release was extremely slow.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antigens, Neoplasm. Drug Carriers / chemistry. Drug Carriers / pharmacokinetics. Histocompatibility Antigens. Mice. Neoplasms / drug therapy. Treatment Outcome

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19090781.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Drug Carriers; 0 / Histocompatibility Antigens; 0 / Peptides; 0 / Prodrugs; 0 / tumor-associated transplantation antigen; 80168379AG / Doxorubicin; 9044-05-7 / carboxymethyl dextran; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


20. Masci P, Borden EC: Malignant melanoma: treatments emerging, but early detection is still key. Cleve Clin J Med; 2002 Jul;69(7):529, 533-4, 536-8 passim
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma: treatments emerging, but early detection is still key.
  • Although we are beginning to develop treatment options for malignant melanoma, earlier recognition of potential primary melanomas remains the most effective way to increase survival in this highly malignant disease.
  • This article reviews prominent risk factors for melanoma, key physical findings in at-risk patients, new melanoma staging guidelines, and recent and emerging therapy options.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Dysplastic Nevus Syndrome / diagnosis. Female. Heliotherapy / adverse effects. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Neoplasm Staging. Precancerous Conditions / diagnosis. Recombinant Proteins. Risk Factors. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12109636.001).
  • [ISSN] 0891-1150
  • [Journal-full-title] Cleveland Clinic journal of medicine
  • [ISO-abbreviation] Cleve Clin J Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 43
  •  go-up   go-down


21. Makhado DA: Dermatological conditions in young adults (20-35 years)--part 1. SADJ; 2007 May;62(4):188-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Skin Diseases / drug therapy
  • [MeSH-minor] Acne Keloid / drug therapy. Acne Keloid / pathology. Acne Vulgaris / drug therapy. Acne Vulgaris / pathology. Adult. Condylomata Acuminata / pathology. Dysplastic Nevus Syndrome / pathology. Dysplastic Nevus Syndrome / surgery. Eczema, Dyshidrotic / drug therapy. Eczema, Dyshidrotic / pathology. Female. Humans. Lupus Erythematosus, Discoid / drug therapy. Lupus Erythematosus, Discoid / pathology. Male. Melanosis / drug therapy. Melanosis / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907589.001).
  • [ISSN] 1029-4864
  • [Journal-full-title] SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging
  • [ISO-abbreviation] SADJ
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] South Africa
  • [Number-of-references] 1
  •  go-up   go-down






Advertisement